文献速递骨质疏松与代谢性骨病

停用地舒单抗后RANKL与TRAcP 5b的变化提示RANKL介导的破骨细胞形成导致骨吸收增加

Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption.
PubMed 文献 · Osteoporos Int · 2022-12-22

61例脊柱和髋部骨密度T值大于-2.5且停用长期地舒单抗的患者随机分配至末次注射后6、9或12个月或骨转换高时接受唑来膦酸治疗。6个月组RANKL较高而TRAcP 5b较低,9和12个月组CTX和PINP较高,TRAcP 5b与RANKL负相关,提示RANKL蓄积增加活跃破骨细胞数量导致骨转换增加。

要点

  • 停用长期地舒单抗后6个月RANKL水平高,9和12个月时RANKL较低但TRAcP 5b较高。
  • 9个月和12个月组CTX和PINP高于6个月组,差异有统计学意义(p < 0.001)。
  • TRAcP 5b与RANKL负相关(R = -0.54),末次注射后时间与CTX、PINP、TRAcP 5b正相关,与RANKL负相关。

核心结论

  • 停用长期地舒单抗后RANKL水平高,最可能导致活跃破骨细胞数量增加(以TRAcP 5b反映),进而引起骨转换增加。

研究设计与样本

  • 61例脊柱和髋部骨密度T值大于-2.5且停用长期地舒单抗的患者随机分配至末次注射后6个月(6个月组,n = 20)、9个月(9个月组,n = 20)或12个月或骨转换高时(12个月组,n = 21)接受唑来膦酸治疗。
  • 在开始唑来膦酸治疗前即刻测量骨转换标志物。

主要发现

  • 9个月组和12个月组CTX和PINP高于6个月组(p < 0.001)。
  • 6个月组TRAcP 5b低于其他两组,RANKL高于其他两组(p < 0.001)。
  • TRAcP 5b与RANKL负相关(R = -0.54)。
  • 末次地舒单抗注射后时间与CTX(R = 0.56)、PINP(R = 0.72)、TRAcP 5b(R = 0.51)正相关,与RANKL负相关(R = -0.70)(所有p < 0.001)。
  • 各组间OPG无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: In patients discontinuing long-term denosumab, RANKL levels are high 6 months after the last denosumab injection. Nine and 12 months after the last denosumab injection RANKL levels are lower, but TRAcP 5b levels are higher, suggesting that accumulated RANKL increases the number of active osteoclasts. PURPOSE: The rapid increase in bone turnover occurring when discontinuing long-term treatment with denosumab (DMAB), an antibody that neutralizes receptor activator of nuclear factor kappa-B ligand (RANKL) is not fully understood. We aimed to investigate the mechanisms underlying the rebound activation of bone resorption by measuring tartrate-resistant acid phosphatase 5b (TRAcP 5b), RANKL, osteoprotegerin (OPG), C-terminal collagen crosslinks (CTX), and procollagen type I N-propeptide (P1NP) in patients discontinuing long-term DMAB. METHODS: Sixty-one patients with BMD T-score > - 2.5 at the spine and hip discontinuing long-term DMAB were randomized to treatment with zoledronate (ZOL) 6 months (6 M group, n = 20), 9 months (9 M group, n = 20) or 12 months after the last DMAB injection or when bone turnover was high (12 M group, n = 21). Bone turnover markers were measured immediately before initiation of ZOL treatment. RESULTS: We found higher CTX and PINP in the 9 M and 12 M groups compared to the 6 M group (p < 0.001). In the 6 M group, TRAcP 5b was lower and RANKL higher than in the other two groups (p < 0.001). TRAcP 5b correlated negatively with RANKL (R = - 0.54), and time since the last DMAB injection correlated positively with CTX (R = 0.56), PINP (R = 0.72), TRAcP 5b (R = 0.51) and negatively with RANKL (R = - 0.70) (p < 0.001 for all). We found no difference in OPG between groups. CONCLUSION: Following discontinuation of long-term DMAB, we find high levels of RANKL, which most likely result in an increase in the number of active osteoclasts (illustrated by TRAcP5b) causing an increased bone turnover.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Sølling AS, Harsløf T, Jørgensen NR, et al. Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption. Osteoporos Int. 2022. PMID: 36543965. doi:10.1007/s00198-022-06651-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。